期刊
SEMINARS IN DIAGNOSTIC PATHOLOGY
卷 39, 期 3, 页码 137-147出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.semdp.2021.12.001
关键词
Endometrial cancer; Endometrial precancer; Endometrial atypical hyperplasia (AH); Endometrioid intraepithelial neoplasia (EIN); Pax2; Pten; beta-catenin
Early detection of endometrial cancer and its precancers is crucial but challenging. Advances in morphology, molecular genetics, biomarker validation, and digital image analysis have improved our understanding of diagnosis.
Early detection of endometrial cancer, especially its precancers, remains a critical and evolving issue in patient management and the quest to decrease mortality due to endometrial cancer. Due to many factors such as specimen fragmentation, the confounding influence of endogenous or exogenous hormones, and variable or overlapping histologic features, identification of bona fide endometrial precancers and their reliable discrimination from benign mimics remains one of the most challenging areas in diagnostic pathology. At the same time, the diagnosis of endometrial precancer, or the presence of suspicious but subdiagnostic features in an endometrial biopsy, can lead to long clinical follow-up with multiple patient visits and serial endometrial sampling, emphasizing the need for accurate diagnosis. Our understanding of endometrial precancers and their diagnosis has improved due to systematic investigations into morphologic criteria, the molecular genetics of endometrial cancer and their precursors, the validation of novel biomarkers and their use in panels, and more recent methods such digital image analysis. Although precancers for both endometrioid and non-endometrioid carcinomas will be reviewed, emphasis will be placed on the former. We review these advances and their relevance to the histopathologic diagnosis of endometrial precancers, and the recently updated 2020 World Health Organization (WHO) Classification of Female Genital Tumors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据